Albumin-nanoprotease drug delivery system, preparation method and application thereof
By utilizing the albumin-nanozyme drug delivery system, the targeted accumulation of albumin and the antioxidant and anti-inflammatory effects of nanozymes are leveraged to solve the safety and efficacy issues of existing nanomedicine delivery systems, achieving efficient, long-term drug release and high bioavailability at atherosclerotic plaques.
Patent Information
- Application Number
- CN202610640296.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-05-11
- Publication Date
- 2026-07-24
AI Technical Summary
Existing nanomedicine delivery systems face a trade-off between safety and efficacy in the treatment of atherosclerosis, including limitations in near-infrared light release, immune risks associated with xenotransplantation, and limited drug utilization.
The albumin-nanozyme drug delivery system is used to encapsulate the drug with albumin, thereby improving drug bioavailability by utilizing the targeted accumulation effect of albumin and the antioxidant and anti-inflammatory effects of nanozymes.
It significantly improves drug retention rate and efficacy at atherosclerotic plaques, reduces toxic side effects, and achieves targeted co-delivery and long-term local release of multiple drugs.
Smart Images

Figure CN122440595A_ABST
Abstract
Citation Information
Patent Citations
Astaxanthin nano-carrier for atherosclerosis treatment and preparation method thereof
CN116898809A
Nano-drug delivery system HALA coated Ag2S as well as preparation method and application thereof
CN118304428A
Macrophage membrane functionalized manganese dioxide nano-drug as well as preparation method and application thereof in treatment of atherosclerosis
CN119548473A